Compare
Rybrevant Faspro vs. Rybrevant

Rybrevant Faspro (amivantamab-vmjw / hyaluronidase-vhjc) is a combination medication used to treat adults with non-small cell lung cancer (NSCLC) that have specific EGFR mutations. The medication is injected under the skin in your stomach by a healthcare professional. Depending on your treatment plan, you might receive it alone or with other cancer medications. Common side effects include rash, muscle or joint pain, and skin infections around the nails.

• Used with lazertinib as a first-choice treatment
• Used with carboplatin and pemetrexed if the cancer has gotten worse or it didn't respond well to EGFR inhibitors
• Used with carboplatin and pemetrexed as a first-choice treatment
• Used alone if the cancer has gotten worse or didn't respond well to platinum-based chemotherapy

Used with lazertinib:

• Rash (80%)
• Infected skin around the nail (58%)
• Muscle and joint pain (50%)
• Tiredness (37%)
• Mouth sores (36%)
• Swelling (34%)
• Nausea (30%)
• Diarrhea (22%)
• Vomiting (22%)
• Constipation (22%)
• Reduced appetite (22%)
• Headache (21%)
• Changes in certain blood tests

Note: Side effects might differ if you use Rybrevant Faspro (amivantamab / hyaluronidase) alone or with chemotherapy

• Allergic and injection-related reactions
• Lung problems
• Blood clots (when used with lazertinib)
• Skin problems
• Eye problems
• Harm to unborn babies

Rybrevant (amivantamab-vmjw) is an FDA approved injection used to treat adults with non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It's given as an infusion through your vein (IV), and your dosing schedule depends on the type of lung cancer being treated. You also might receive it with other cancer medications. Common side effects include infusion-related reactions, rash, tiredness, and skin infections around the nails.

Adults with advanced or metastatic NSCLC with certain EGFR mutations:

• Used with lazertinib as a first-choice treatment
• Used with carboplatin and pemetrexed if the cancer has gotten worse or it didn't respond well to EGFR inhibitors
• Used with carboplatin and pemetrexed as a first-choice treatment
• Used alone if the cancer has gotten worse or didn't respond well to platinum-based chemotherapy

Used with lazertinib:

• Rash
• Infected skin around the nail
• Muscle and joint pain
• Mouth sores
• Swelling
• Tingling sensation
• Tiredness
• Diarrhea
• Constipation
• COVID-19
• Dry skin
• Bleeding
• Reduced appetite
• Itchy skin
• Nausea
• Changes in certain blood tests

Used with carboplatin and pemetrexed:

• Rash
• Infected skin around the nail
• Tiredness
• Nausea
• Mouth sores
• Constipation
• Swelling
• Reduced appetite
• Muscle and joint pain
• Vomiting
• COVID-19
• Changes in certain blood tests

Used alone:

• Rash
• Infected skin around the nail
• Muscle and joint pain
• Shortness of breath
• Nausea
• Tiredness
• Swelling
• Mouth sores
• Cough
• Constipation
• Vomiting
• Changes in certain blood tests

• Infusion-related reactions
• Lung problems
• Blood clots (when used with lazertinib)
• Skin problems
• Eye problems
• Harm to the unborn baby